Kava: A relaxing beverage with therapeutic benefits

+Natural health
In print

Kava: A relaxing beverage with therapeutic benefits

Phil Rasmussen

kava CR Forest and Kim Starr, CC by-SA 3.0
The kava plant in Maui, Hawaii [Image: Forest and Kim Starr, CC BY-SA 3.0]

Pharmacist and medical herbalist Phil Rasmussen traces the chequered history of kava, which is famous for its anti-anxiety and sleep-promoting properties

Kava (Piper methysticum) was first domesticated in the Pacific Islands about 3000 years ago. Numerous varieties exist, and today it is widely cultivat
  1. Hansel R, Beiersdorff HV. Arzneim Forsch 1959;9:581.
  2. Keller F, Klohs MW. Lloydia 1963;26:1.
  3. Meyer HJ. Kin Wochenschr 1965;43:46970.
  4. Kretzschmar R. In: Loew D, Rietbrock N (eds). Phytiopharmaka in Forschung und Klinischer Anwendung, p2938. Darmstadt, Germany: Verlag Steinkopff; 1995.
  5. Garrett KM, Basmadjian G, Khan IA, et al. Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice. Psychopharmacology2003;170(1):33–41.
  6. Krum BN, Molz de Freitas C, Chiapinotto Ceretta AP, et al. Kava decreases the stereotyped behavior induced by amphetamine in mice. J Ethnopharmacol 2021;265:113293.
  7. Scholing WE, Clausen HD. On the effect of d,l-kavain: experience with neronika. Med Klin 1977;72(3233):130106.
  8. Kinzler E, Krömer J, Lehmann E. Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks]. Arzneimittelforschung 1991;41(6):58488.
  9. Lindenberg D, Pitule-Schodel H. D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness. Forschr Med 1990;108:49.
  10. Warnecke G., Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness and tolerance of Kava extract WS 1490. Fortschr Med 1991;109:11922.
  11. Volz HP, Keiser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders – a randomised placebo-controlled 25 week outpatient trial. Pharmacopsychiatry 1997;30(1):15.
  12. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 2000;20(1):84–89.
  13. Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytotherapy Res 2005;19(3):183–88.
  14. Smith K, Leiras C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: A systematic review and analysis of randomized clinical trials. Complementary Therapies in Clinical Practice 2018;33:107–17.
  15. Sarris J, Byrne GJ, Bousman CA, et al. Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Aust N Z J Psychiatry 2020;54(3):28897.
  16. Holm E. The action profile of D,L-kavain. Cerebral sites and sleep-wakefulness-rhythm in animals. Arzneimittelforschung 1991;41(7):67383.
  17. Davies LP, et al. Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 1992;71(2):12026.
  18. Jussofie A, et al. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology 1994;116(4):46974.
  19. Boonen G, Haberlein H. Influence of genuine kavapyrone enantiomers on the GABA-A binding site. Planta Medica 1998;64:50406.
  20. Walden J, et al. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 1997;21(4):697706.
  21. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998;22(7):110520.
  22. Dinh LD, Simmen U, Bueter KB, et al. Interaction of various Piper methysticum cultivars with CNS receptors in vitro. Planta Med 2001;67(4):30611.
  23. Wang Y, Su C, Zhang B, et al. Biological activity, hepatotoxicity, and structure-activity relationship of kavalactones and flavokavins, the two main bioactive components in kava (Piper methysticum). Evid Based Complement Alternat Med 2021;2021:6851798.
  24. Singh YN. Kava: an overview. J Ethnopharmacol 1992;37(1):1345.
  25. Huck O, You J, Han X, et al. Reduction of articular and systemic inflammation by kava-241 in a Porphyromonas gingivalis-induced arthritis murine model. Infection and Immunity2018;86(9):e0035618.
  26. Botello JF, Corral P, Bian T, et al. Kava and its kavalactones inhibit norepinephrine-induced intracellular calcium influx in lung cancer cells. Planta Medica 2020;86(1):26–31.
  27. Bian T, Ding H, Wang Y, et al. Suppressing the activation of protein kinase A as a DNA damage-independent mechanistic lead for dihydromethysticin (DHM) prophylaxis of NNK-induced lung carcinogenesis. Carcinogenesis 2022:bgac031.
  28. Pan H, Liu F, Wang J, et al. Dihydromethysticin, a natural molecule from Kava, suppresses the growth of colorectal cancer via the NLRC3/PI3K pathway. Molecular Carcinogenesis2020;59(6):575–89.
  29. Jandial DD, Krill LS, Chen L, et al. Induction of G2M arrest by flavokawain A, a kava chalcone, increases the responsiveness of HER2-overexpressing breast cancer cells to herceptin. Molecules (Basel, Switzerland) 2017;22(3):462.
  30. Stevinson C, Huntley A, Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Safety2002;25(4):251–61.
  31. LaPorte E, Sarris J, Stough C, et al. Neurocognitive effects of kava (Piper methysticum): a systematic review. Human Psychopharmacology 2011;26(2):102–11.
  32. Sarris J, Laporte E, Scholey A, et al. Does a medicinal dose of kava impair driving? A randomized, placebo-controlled, double-blind study. Traffic Inj Prev 2013;14(1):13–17.
  33. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994;31(1):8997.
  34. Duffield PH, Jamieson D. Development of tolerance to kava in mice. Clin Exp Pharmacol Physiol 1991;18(8):57178.
  35. Teschke R. Kava hepatotoxicity--a clinical review. Ann Hepatol 2010;9(3):25165.
  36. Schmidt M, Morgan M, Bone K, et al. Kava: A risk-benefit assessment. In: Mills S, Bone K (eds). The Essential Guide to Herbal Safety, pp. 155221. St. Louis, MO: Elsevier, Churchill, Livingstone; 2005.
  37. Schmidt M. German court ruling reverses kava ban; German regulatory authority appeals decision. HerbalGram 2014;103:3842.
  38. Kuchta K, Schmidt M, Nahrstedt A. German kava ban lifted by court: The alleged hepatotoxicity of kava (Piper methysticum) as a case of ill-defined herbal drug identity, lacking quality control, and misguided regulatory politics. Planta Med 2015;81(18):164753.
  39. Thomsen M, Schmidt M. Health policy versus kava (Piper methysticum): Anxiolytic efficacy may be instrumental in restoring the reputation of a major South Pacific crop. J Ethnopharmacol 2021;268:113582.
  40. NZ Association of Medical Herbalists, Rasmussen PL. Submission to the MCC concerning proposal to harmonise the classification of kava with that of Australia. May 2005.
  41. Natural Health Products New Zealand, Rasmussen PL. Submission to FSANZ concerning proposed changes to the food standard regulating kava use. 22 December 2021.